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Myc inhibition is effective against glioma and
reveals a role for Myc in proﬁcient mitosis
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Isabel Cuartas3,4, Sara Redondo-Campos3,4, Gerard Folch3,4, Alba Gonza`lez-Junca`3,4, Nicole M. Sodir1,5,
Daniel Masso´-Valle´s3,4, Marie-Eve Beaulieu3,4, Lamorna B. Swigart1, Margaret M. Mc Gee6,
Maria Patrizia Somma2, Sergio Nasi2, Joan Seoane3,4,7, Gerard I. Evan5 & Laura Soucek3,4
Gliomas are the most common primary tumours affecting the adult central nervous system
and respond poorly to standard therapy. Myc is causally implicated in most human tumours
and the majority of glioblastomas have elevated Myc levels. Using the Myc dominant
negative Omomyc, we previously showed that Myc inhibition is a promising strategy for
cancer therapy. Here, we preclinically validate Myc inhibition as a therapeutic strategy
in mouse and human glioma, using a mouse model of spontaneous multifocal invasive
astrocytoma and its derived neuroprogenitors, human glioblastoma cell lines, and patient-
derived tumours both in vitro and in orthotopic xenografts. Across all these experimental
models we ﬁnd that Myc inhibition reduces proliferation, increases apoptosis and remarkably,
elicits the formation of multinucleated cells that then arrest or die by mitotic catastrophe,
revealing a new role for Myc in the proﬁcient division of glioma cells.
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G
liomas are the most frequent primary tumours affecting
the adult human central nervous system. The World
Health Organization deﬁnes four brain tumour classes
(I, II, III, IV) on the basis of their morphological features and
predicted clinical behaviour. The most lethal is grade IV
glioblastoma (GBM), with a median survival of only 15
months1,2. However, all grades respond poorly to conventional
therapy3. Gliomas are presumed to arise from mature glia or
neural stem cells and diffusely inﬁltrate the surrounding tissue3,
making surgical resection very difﬁcult. Gliomas may be
astrocytic, oligodendritic or of mixed lineage and are all
characterized by refractoriness to apoptosis and marked
genomic instability, both of which are thought to contribute to
their poor response to chemo- and radiotherapy3. Recurring
alterations observed in gliomas include ampliﬁcation and
activating mutations of EGFR, precocious receptor tyrosine
kinase signalling, deletion of NF1 and elevated levels of p21ras
signalling (reviewed in ref. 3). In particular, signalling through the
Ras network is essential for both proliferation4 and angiogenesis5
of human malignant astrocytomas.
Myc is a bHLHZip transcription factor, causally implicated in
most human cancers6. Myc controls diverse cellular functions,
including cell growth and proliferation, differentiation and
programmed cell death. Its expression in normal cells is tightly
regulated by mitogen availability but this control is compromised
in tumour cells, either as a consequence of constitutive upstream
oncogenic signals or direct mutation in the myc genes
themselves7. Myc expression correlate with glioma grade8 and
some 60–80% of GBM exhibit elevated Myc levels9. In addition,
transgenic Myc expression in the astrocytic lineage of mice is
sufﬁcient to cause gliomas resembling the human disease10.
Increased c-Myc activity downstream of p53 and Pten mutations
is also causally associated with impaired neuronal differentiation
and enhanced self-renewal capacity of GBM tumour-initiating
cells11. Consistently, Myc knockdown in Pten / /p53 /
double null neurospheres reduces their tumorigenic potential11.
Others have proposed a central role for Myc also in the
progression of gliomas driven by various different
mutations12,13 suggesting that Myc inhibition could be effective
in multiple types of glioma.
To assess the therapeutic potential of Myc inhibition in vivo we
previously employed a dominant negative mutant of the Myc
dimerization domain, termed Omomyc. Omomyc has an altered
dimerization speciﬁcity, allowing it to sequester Myc away from
its obligate partner Max and so inhibiting Myc-dependent
transcriptional activation14,15. Making use of a TRE-Omomyc;
CMVrtTA mouse model, in which Omomyc is widely expressed
upon doxycycline administration16, we showed that systemic Myc
inhibition triggers rapid regression of both KRasG12D-driven
lung tumours16,17 and T antigen-driven pancreatic b-cell
insulinomas18 in mice. Remarkably, such systemic Myc
inhibition elicits only very mild and well-tolerated side effects
in normal tissues16. Moreover, we observed no evolution of
resistance to Myc inhibition in either tumour model, consistent
with the unique and irreplaceable role Myc has as an integrator of
proliferative transcriptional programs17.
Here, we perform a comprehensive analysis of the therapeutic
impact of systemic Myc inhibition in both progression and
maintenance of glioma, comparing for the ﬁrst time mouse
and human experimental models, and investigate its actual
mechanism of action.
Results
Myc inhibition increases survival of GFAP-V12Ha-Ras mice.
To determine the therapeutic impact of systemic Myc inhibition
in both progression and maintenance of glioma, we combined
our switchable TRE-Omomyc;CMVrtTA mouse with the well-
characterized GFAP-V12Ha-Ras (ref. 19), a spontaneous mouse
model of multifocal invasive astrocytoma in which the activated
form of Ha-Ras is driven by the glial ﬁbrillary acidic protein
promoter (GFAP; Fig. 1a). The molecular and pathological pro-
gression of disease in GFAP-V12Ha-Ras mice resembles that of
diffuse astrocytomas in humans, exhibiting reproducible kinetics
of tumour progression, from astroglial hyperplasia (starting from
1–3 weeks of age) through to low- and high-grade gliomas20.
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Figure 1 | Myc inhibition confers a survival advantage in GFAP-V12Ha-Ras
mice. (a) To obtain a mouse model of spontaneous glioma in which
Omomyc expression could be activated upon doxycycline treatment,
TRE-Omomyc;CMVrtTA mice were crossed with GFAP-V12Ha-Ras mice,
giving the triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras.
(b) Kaplan–Meier curve showing that Omomyc expression confers a
signiﬁcant survival advantage to V12Ha-Ras expressing mice. Eight-week-
old mice, untreated or treated with Omomyc, were monitored for symptom-
free survival up to 57 weeks of age.þOmomyc: TRE-Omomyc;CMVrtTA;
GFAP-V12Ha-Ras triple transgenics plus doxycycline (n¼8).Omomyc: six
vehicle-treated TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras triple transgenics
and two CMVrtTA;GFAP-V12Ha-Ras treated with doxycycline, to control for
any doxycycline effect (n¼8) P¼0.014 by log-rank test. No effect of
doxycycline was observed on tumour latency. (c) Representative pictures of
GFAP immunostaining from the brains of mice included in the survival curve
above. The panels on the right are higher magniﬁcation images of regions
indicated by the black boxes. Control mice present dense GFAP-positive
cells compared with Omomyc-treated mice.
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Omomyc was induced in TRE-Omomyc;CMVrtTA;GFAP-
V12Ha-Ras mice from postnatal week 8 with doxycycline and
the animals then monitored to determine symptom-free survival.
Strikingly, at 57 weeks of age, all Omomyc-expressing mice (8/8)
were asymptomatic with no evidence of disease progression
(Fig. 1b,c). By contrast, at the same time point only 25% of
the untreated control GFAP-V12Ha-Ras mice were still alive, the
majority having been euthanized by this time point due to the
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Figure 2 | Myc inhibition reduces proliferation and viability of V12Ha-Ras neuroprogenitors. (a) Neuroprogenitor cells freshly isolated from the
subventricular zone (SVZ) of adult (3 months old) asymptomatic triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras control mice were grown as
neurospheres in culture in serum-free medium supplemented with growth factors (EGF and FGF). Immunostaining for GFAP (green) and Ki67 (red) are
shown. Nuclei were counterstained with Hoechst (blue). (b,c) NPG growth curves. Neuroprogenitors were plated as single cells in 12-well plates and
treated with doxycycline (þDox) or untreated (–Dox) for 3 days. Triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras cells expressing Omomyc show
a signiﬁcant reduction in the total number of cells after 3 days of treatment, compared with the untreated cultures. (P-value¼0.0168, calculated by t-test;
b). Notably, 3 days of Omomyc expression in control TRE-Omomyc;CMVrtTA does not affect signiﬁcantly their growth rate (c). Data are shown as
means±s.e. of triplicates (n¼ 2). (d,e) Cell death was assessed by Trypan blue staining. Triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras NPGs
have elevated numbers of dead cells after Omomyc expression for 3 days (d), whereas there is no difference in double transgenic TRE-Omomyc;CMVrtTA
NPGs (e). Data are shown as meanþ s.e. of triplicates. P-values were calculated by t-test. (f) BrdU staining of triple transgenic TRE-Omomyc;CMVrtTA;
GFAP-V12Ha-Ras and control TRE-Omomyc;CMVrtTA cells treated with doxycycline for 3 days or untreated. Data represent the mean of triplicatesþ s.e.
(n¼ 3). P-values were calculated by t-test. (g) Omomyc expression impairs the self-renewal ability of triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-
Ras NPGs. Single neuroprogenitor cells were plated at a clonal density (500 per well) in a 12-well plate and treated or not with doxycycline. After 21 days,
the number of spheres was evaluated. Data are shown as meansþ s.e. of triplicates (n¼ 2). P-values were calculated by t-test.
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appearance of progressive ataxia and neurological symptoms,
associated with astrocytic hyperplasia and increased intracranial
pressure (Fig. 1c).
Of note, mice subjected continuously to Myc inhibition showed
no sign of any distress or discomfort, conﬁrming the previously
reported well-tolerated and mild side effects elicited by Myc
inhibition in normal tissue maintenance and homeostasis16.
Myc inhibition limits growth of transformed neuroprogenitors
To understand how Myc inhibition prevents glioma formation,
we ﬁrst investigated the cellular compartment previously
identiﬁed in different glioma models as the putative cell of origin
of the tumour: the neuroprogenitor (NPG) cells21,22. Recent
reports demonstrate that glioma cells share features with neural
stem and progenitor cells, including a high proliferation rate, and
self-renewal and migration abilities3,23,24. As Myc has a
demonstrated role in normal and neoplastic stem cell biology,
we assessed the impact of Omomyc expression in primary NPG
cells derived from our TRE-Omomyc;CMVrtTA;GFAP-V12
Ha-Ras mice.
Neural progenitor cells were isolated from the subventricular
zones (SVZs) of either adult triple transgenic TRE-Omo-
myc;CMVrtTA;GFAP-V12Ha-Ras or control double transgenic
TRE-Omomyc;CMVrtTA brains and grown as neurospheres in
serum-free medium supplemented with growth factors (EGF and
bFGF). As expected, the cells stayed strongly positive for GFAP
expression (Fig. 2a). In these cultured NPGs, Omomyc mRNA
expression was clearly detectable by 48 h of starting doxycycline
treatment, whereas no Omomyc signal was detectable in
untreated cells (Supplementary Fig. 1). Of note, even though
NPG cultures derived from the triple transgenic TRE-Omomyc;
CMVrtTA;GFAP-V12Ha-Ras mouse expand signiﬁcantly more
than non-V12Ha-Ras-expressing TRE-Omomyc;CMVrtTA cells,
Omomyc expression in Ras-transformed cells profoundly
decreased total cell number at 3 days (Fig. 2b). At this same
3-day time point, the control cell culture had barely expanded
and Omomyc expression had negligible effect on cell number
(Fig. 2c).
To determine the mechanism by which Omomyc expression
blocks expansion of NPG cell cultures, we ﬁrst examined cell
death. Omomyc expression induced signiﬁcant cell death in
Ras-transformed NPGs but had no effect on the viability of
control TRE-Omomyc;CMVrtTA cells (Fig. 2d,e). Omomyc also
profoundly inhibited NPG proliferation: after 3 days of
doxycycline treatment, we observed a signiﬁcant reduction in
the percentage of BrdU positive cells in TRE-Omomyc;CMVrtTA;
GFAP-V12Ha-Ras NPGs, down to a rate similar to that observed
in TRE-Omomyc;CMVrtTA controls, in which no difference was
observed as a consequence of Omomyc expression (Fig. 2f).
Hence, Omomyc exerts its effect on Ras-transformed cells both
by reducing proliferation and enhancing cell death.
Myc inhibition impairs NPG self-renewal capacity. According
to the cancer stem cell hypothesis, the refractoriness of gliomas to
eradication by chemo- and radiotherapy is due to a subpopula-
tion of cells within the tumour that has stem cell features,
including a high proliferation rate and self-renewal capacity.
To investigate whether Myc inhibition impairs these character-
istics, we employed a neurosphere self-renewal assay, measuring
the number of cells able to reform a secondary neurosphere from
a single cell. In this assay, NPGs are seeded at clonal density (500
single cells per well), then cultured with or without doxycycline
for 21 days, at which point the number of spheres in each well is
determined. Notably, Omomyc expression impairs the self-
renewal ability of both the Ras-transformed and the control cells
(Fig. 2g and Supplementary Fig. 1b), consistent with the crucial
role ascribed to Myc proteins in promoting and maintaining self-
renewal and stemness of both neoplastic and normal progenitor
cells25,26.
Myc inhibition reverses the symptoms of GFAP-V12Ha-Ras
mice. To test the therapeutic utility of Myc inhibition in advanced
gliomas, we evaluated the impact of Omomyc expression in TRE-
Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice presenting already
clear neurological symptoms. Due to the variable tumour latency
of our colony (see Fig. 1b, untreated–Omomyc animals), such
symptoms appeared stochastically: the animals were initially
hyperactive and often aggressive, but eventually became almost
catatonic and unresponsive to external stimuli. At this point, they
were treated with Omomyc. After 7 days of Myc inhibition, the
therapeutic effect was dramatic. As documented by the movie
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Figure 3 | Histological analysis of symptomatic mice. Representative GFAP immunostaining of normal CMVrtTA and triple transgenic TRE-Omomyc;
CMVrtTA;GFAP-V12Ha-Ras brains. Left panels show that astrocytic density is reduced in Omomyc-expressing mice. Center panels focus on residual
GFAP-positive regions. Right panels show higher magniﬁcation of astrocytes and active microglia.
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(Supplementary Movie 1), mice were typically lethargic at the
commencement of treatment, failed to groom and lacked appetite.
After 7 days of Myc inhibition however, treated mice were active,
responded again to external stimuli and were able to move, eat,
drink and groom (Supplementary Movie 2).
Histological analysis of treated versus untreated samples clearly
showed that untreated symptomatic mice exhibited regions with
high density, GFAP-positive, pleomorphic and inﬁltrative astro-
cytes, typical histopathological features of human malignant
astrocytomas (Fig. 3, middle versus upper panels). By contrast,
the improved health of treated animals was associated with
markedly reduced astrocytic (GFAP positive) cell density (Fig. 3,
lower panels). Further immunohistochemical analysis of the
residual GFAP-positive regions in Myc-inhibited symptomatic
mice revealed a signiﬁcant decrease in the number of proliferating
cells compared with untreated mice (3.63% versus 7.83%
positivity for the proliferation marker Ki67; Fig. 4a,b). In
addition, we noted a small but signiﬁcant increase in the number
of apoptotic (TUNEL-positive) cells in Omomyc-expressing
mouse brains when compared with Omomyc-negative controls
(1.74% versus 0.48%; Fig. 4a,c), indicating that cell death
contributes—at least to some degree—to the reduced cellular
density observed upon Myc inhibition. A notable reduction in
total cell number after Omomyc expression was conﬁrmed by
determining the number of nuclei present in ﬁve whole
macroscopic ﬁelds (see total number of nuclei in treated versus
untreated animals in Fig. 4b,c).
Intriguingly, we observed that in the GFAP-positive regions
remaining after Omomyc treatment, there was a signiﬁcant
increase in multinucleated GFAP-positive cells compared with
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Figure 4 | Effects of Myc inhibition in the brain of GFAP-V12Ha-Ras symptomatic mice. (a) Symptomatic triple transgenic TRE-Omomyc;CMVrtTA;
GFAP-V12Ha-Ras mice were treated with doxycycline for 7 days (n¼ 2) or untreated (n¼ 3). Histological analysis (left panels) shows a reduction in Ki67
positive (proliferating) cells and an increase in dying TUNEL-positive cells in Omomyc-expressing mice. (b) Quantiﬁcation of the Ki67 positivity from the
histological analysis in a. The percentage of proliferating cells is shown in the graph, and the total number of cells counted in ﬁve ﬁelds is also indicated in
the table. (c) Quantiﬁcation of the TUNEL positivity from the histological analysis described above. The percentage of TUNEL-positive cells is shown in the
graph, and the total number of cells counted in ﬁve ﬁelds is also indicated in the table. (d) Omomyc treatment causes the appearance of multinucleated
cells. Symptomatic triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice were treated with doxycycline for 7 days. Histological analysis was
performed on isolated brains to look for GFAP-positive astrocytes in tumour regions (green dye). Nuclei were counterstained with Hoechst (coloured pink
here after merging with the GFAP images to facilitate visualization of the nuclei). (e) Quantiﬁcation of the number of multinucleated GFAP-positive nuclei
after Omomyc treatment (n¼ 2) for 7 days compared with untreated mice (n¼ 2). The average of two mice is shownþ s.e. For each mouse, a minimum of
10 microscopic ﬁelds and 300 cells were scored. Data are shown as meansþ s.e. P-value was calculated by Student’s t-test.
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untreated animals, suggestive of an effect of Myc inhibition on
ploidy and mitosis of astrocytoma cells (Fig. 4d,e).
Myc inhibition triggers mitotic crisis in human GBM cells. To
ascertain whether the antitumorigenic effect of Myc inhibition in
the mouse model might translate into an analogous therapeutic
impact in a human system, we investigated the effect of Omomyc
expression in cell lines derived from human grade IV gliomas.
U87MG cells27 were infected with retroviruses directing the
expression of either GFP (control) or a GFP-Omomyc fusion
protein. Consistent with our in vivo results in the GFAP-V12
Ha-Ras mouse model, the total U87MG cell number was reduced
on Omomyc induction, whereas GFP expression alone had no
such effect (Fig. 5a). In addition, we observed a signiﬁcant
increase in cell death in U87MG cells expressing Omomyc,
compared with control cells (Fig. 5b). Using a doxycycline-
switchable lentiviral vector to drive expression of Omomyc, we
also observed an increase in the proportion of ﬂattened,
senescent-like cells that stained positively for b-galactosidase
(Fig. 5c). Broadly similar observations were made in Omomyc-
expressing U373MG cells, which notably are mutant for p53
(Supplementary Fig. 2), although the cell ﬂattening seen in
U87MG cultures after Omomyc expression was not recapitulated
(Supplementary Fig. 2c).
Cytological examination of ﬁxed Omomyc-expressing U87MG
cells stained for tubulin and DNA showed that Omomyc
expression causes a reduction in the mitotic index (0.96% versus
1.86% in control cells), but does not affect mitotic progression
(the prophaseþmetaphase/anaphaseþ telophase ratio was
0.317 in Omomyc-expressing cells and 0.326 in GFP-expressing
cells). A fraction of the dividing cells in Omomyc-expressing
cultures (14.7%) displayed mitotic defects including multipolar
spindles, aberrant chromosome segregation, chromatin bridges
in ana-telophase and an irregular central spindle/midbody
(Fig. 6a (control cells) versus Fig. 6b (Omomyc-expressing cells)).
The ﬁnal outcome of these defective mitoses was the formation
of multinucleated and micronuclei-containing cells (13.6%
after 72 h Omomyc expression; Fig. 6c,d, and Supplementary
Fig. 3a). Similar results were obtained in U373MG cells
with a doxycycline-switchable RFP-Omomyc-expressing vector
(Supplementary Fig. 3b and c), where time-lapse imaging over the
course of 72 h revealed that multinucleated cells enter mitosis but
are unable to complete the mitotic process and may eventually die
(Supplementary Movie 3).
Myc inhibition alters SAE1 expression and PTP1B
phosphorylation. Loss of SUMO activating enzyme (SAE)
expression was recently found to exhibit synthetic lethality
together with Myc overexpression28. One intriguing phenotypic
outcome of SAE knockdown in Myc overexpressing tumour cells
was the appearance of mitotic abnormalities and induction of
mitotic catastrophe28. Interestingly, SAE1 is a direct target of
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Figure 5 | Omomyc causes growth arrest and increases cell death in
U87MG cells. (a) Growth curves of U87MG infected with GFP control or
GFP-Omomyc-expressing retroviruses. Total cell number was quantiﬁed at
the indicated time points. Data are shown as the mean±s.e. of triplicates
from a single experiment representative of three repeats. P-value at 3 days
o0.05; P-value at 4 days o0.01, using a two-tailed t-test. (b) Cell death
was assessed by Trypan blue staining. The number of dead cells was
quantiﬁed at the indicated time points. Data are shown as mean±s.e. of
triplicates. P-values were calculated by t-test. (c) U87MG cells were
infected with a doxycycline-switchable lentiviral vector expressing
Omomyc. Doxycycline treatment increases the number of b-galactosidase
positive, senescent-like cells (left panels: typical b-galactosidase phase
contrast images, right panel: quantiﬁcation). The average of three
experimentsþ s.d. is shown. P-values were calculated by a Student’s t-test.
Figure 6 | Myc inhibition triggers micro- and multinucleation and mitotic abnormalities in U87MG cells. (a) Normal mitosis phases in control U87MG
cells. Tubulin staining (second column and in red in the merged image) shows proper centrosome maturation and spindle assembly, whereas DAPI staining
(ﬁrst column and in blue in the merged image) highlights correct chromosome alignment and subsequent segregation. (b) Mitotic defects in Omomyc-
expressing cells. The same tubulin and DAPI staining as above show that Omomyc induces defects in all mitotic phases, ranging from abnormal multipolar
spindles (prophase and metaphase panels), to chromosome misalignments, segregation errors and lagging chromosomes (anaphase and cytokinesis
panels), and ﬁnally absence of midbody and failed cytokinesis (bottom panel). Mitotic abnormalities involve 14.7% of mitotic ﬁgures in Omomyc-
expressing cells. (c) GFP (green) immunoﬂuorescence and DAPI nuclear counterstain (blue) show that after 24 h of GFP-Omomyc expression, U87MG
cells become multinucleated (bottom panels) whereas that is observed much less frequently in control U87MG (top panel) that express GFP alone. (d) A
representative image of a multinucleated Omomyc-expressing cell: a-tubulin staining (in red) shows that all nuclei belong to the same cell. The arrowhead
indicates a typical micronucleus.
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Myc29. To verify whether SAE1 could be altered in response to
Omomyc expression, we performed western blot analysis on
GBM cell lines. We observed a clear reduction of SAE1 expression
in U87MG (Fig. 7a). Hence, reduced SAE activity could be
responsible for the aberrant nuclei and mitotic catastrophe
observed in this cell line.
On the other hand, in U373MG cells we observed no
downregulation of SAE1 (Fig. 7a). Instead, phosphorylation of
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protein tyrosine phosphatase 1B (PTP1B)—a modiﬁcation
associated with and required for cell death during mitotic
catastrophe30—was observed in response to Myc inhibition
(Fig. 7b), to a degree similar to that caused by Taxol, a well-
characterized microtubule stabilizer and mitosis inhibitor
previously shown to cause PTP1B phosphorylation30.
These results offer at least two new potential mechanisms for
Omomyc-induced cell death in GBM and hint at yet another
aspect of proliferative biology in which Myc is involved.
Myc inhibition limits growth of patient-derived tumours.
To determine whether the antitumorigenic capacity of Myc
inhibition extends to primary human tumour samples and,
consequently, might be clinically applicable in human glioma, we
used a lentiviral vector to drive doxycycline-dependent Omomyc
expression in patient-derived GBM neurosphere cultures derived
from a surgically resected human GBM (Supplementary Fig. 4a).
In culture, Myc inhibition for 2 weeks reduced the overall number
of neurospheres (Fig. 8a) and inhibited self-renewal of spheres
after their dissociation (Fig. 8b). No effect of doxycycline
treatment was observed in neurospheres lacking the Omomyc
lentiviral vector (Supplementary Fig. 4b).
To investigate whether this potentially therapeutic effect might
translate into an objective therapeutic impact, disaggregated
neurospheres were orthotopically inoculated into the brains of
NOD/SCID mice. Animals transplanted with neurospheres
harbouring the Omomyc expression cassette were treated
continuously with either doxycycline from 3 weeks after
transplant (so that Omomyc was expressed throughout tumour
development) or with sucrose in control mice. As expected, Myc
inhibition signiﬁcantly potentiated overall survival (Fig. 8c).
Importantly, once again, we observed the appearance of aberrant
nuclei in nestin-positive cells after Omomyc treatment (Fig. 8d,e).
Discussion
We previously demonstrated in preclinical mouse models that
systemic Myc inhibition is a promising strategy for eradicating
lung cancer16,17 and insulinoma18, inducing profound regression
of tumours, eliciting only very mild side effects in normal tissues
and circumventing the problems with resistance encountered in
other targeted therapies. However, whether or not these
conclusions were applicable to other types of cancer and to
human cancers remained to be established. Here, we extend our
previous studies by showing that Myc inhibition has a similar
effective therapeutic potential for treating glioma, a disease with
an especially dismal prognosis and in urgent need of new
therapies. To do this, we made use of several experimental
models, encompassing both mouse and human systems, including
a Ras-driven mouse model of astrocytoma and NPG cells derived
from it, human GBM cell lines and, importantly, a patient-
derived neurosphere xenograft model. All these studies, both
in vitro and in vivo, indicate that Myc inhibition suppresses
glioma formation, inhibits glioma cell proliferation and survival
and triggers regression of established disease. Unexpectedly, we
also noted that Myc inhibition elicits profound aberrations in
glioma cell mitosis, with the appearance of multinucleated cells,
micronucleation and also multipolar and disorganised spindles.
Time-lapse microscopy conﬁrmed that such aberrant mitotic cells
are unable to complete cell division and many subsequently die.
Although the suppression of Myc might be expected to induce
replicative arrest—given its intimate role in coordinating cell
proliferation—the mechanisms underlying glioma cell mitotic
dysfunction and death are particularly intriguing. Interestingly,
SUMO pathway components have been shown to be required for
cell division and implicated in the control of mitotic chromosome
structure, cell cycle progression, kinetochore function and
cytokinesis31. Here we show that SAE1, a direct target of
Myc29, is downregulated in response to Omomyc expression in
U87MG cells (Fig. 7a), suggesting that a reduction in SAE activity
is responsible for the aberrant nuclei and mitotic catastrophe
observed in this cell line. In contrast, U373MG cells display no
such downregulation of SAE1 levels but Myc inhibition is instead
associated with the phosphorylation of PTP1B, a modiﬁcation
described to trigger cell death during mitotic catastrophe30. The
phosphatase PTP1B has been recently shown to exert antitumour
effects in GBM32, however, it displays tumour-promoting effects
in other cell types; opposing functions may be controlled by
posttranslational modiﬁcations and substrate speciﬁcity. For
example, PTP1B is negatively regulated by sumoylation upon
entry into mitosis33, whereas its phosphorylation by Cdk1
and Plk1 during mitotic arrest promotes its activation and
tumour suppressing activity30. Details of how these opposing
modiﬁcations interact to determine cell fate remain unknown.
In this study we provide evidence to support the hypothesis
that Myc inhibition blocks protein sumoylation (via decreased
SAE1 expression) leading to defective mitosis, and ultimately the
induction of mitotic catastrophe. Failure to satisfy the spindle
assembly checkpoint (SAC) results in protracted M-phase arrest
and sustained activation of mitotic kinases, leading to death
during mitosis. In addition, enhanced PTP1B activity as a result
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of Omomyc-dependent loss of PTP1B sumoylation and conse-
quent gain in its phosphorylation may also directly contribute to
mitotic cell death.
Our results demonstrate that Myc holds a central role in
proﬁcient mitotic programs, the precise molecular mechanism of
which could vary in different cell types depending on the status of
other cell cycle or genome integrity regulators, such as p53. It is
not surprising that the pleiotropic nature of Myc is reﬂected in
the degeneracy of its effectors, some of which control programs
necessary for efﬁcient cell division.
Whether or not the effects of Myc inhibition on mitotic
aberrations are peculiar to GBM cells or also hold in other types
of cancer remains to be established. The mode of action of a Myc
inhibitor—in our case Omomyc—could vary with the context-
speciﬁc role of Myc, whose function ramiﬁes throughout all
aspects of tumorigenesis both at the intracellular and the
extracellular levels. Our data demonstrate that systemic Myc
inhibition appears to be a very promising strategy for treating
glioma, seemingly irrespective of its driving oncogenic lesions.
While direct inhibition of Myc is currently not a pharmacological
option, it may in the future prove possible to inhibit
Myc function, either directly as recently shown using peptides
derived from Myc itself12 or indirectly, as demonstrated for
bromodomain inhibitors34.
Methods
Study design. All the animal studies were performed in accordance with ARRIVE
guidelines and following the three R’s rule of Replacement, Reduction and
Reﬁnement principles.
Mice were housed and treated in accordance with protocols approved by the
Institutional Animal Care and Use Committee at the UCSF (University of
California, San Francisco) and by the CEEA (Ethical Committee for the Use of
Experimental Animals) at the VHIO (Vall d’Hebron Institute of Oncology),
Barcelona.
The anonymized human sample employed was part of the tissue biological
material stored in the tumour bank (TB) at the Hospital Vall d’Hebron. The sample
had been previously collected with a signed patient consent form and its use had
been approved by the Ethics Committee of the Hospital. The sample was a random
one among the GBM patient samples available.
Generation and maintenance of mice. TRE-Omomyc;CMVrtTA mice were
previously described16. GFAP-V12Ha-Ras (Tg(GFAP-Hras1)1Agu) mice were
generated and kindly provided by Dr Abhijit Guha (Toronto Hospital Western
Division-UHN) and Dr David H. Gutmann (WUSM) laboratories. The resulting
triple transgenic TRE-Omomyc;CMVrtTA;GFAP-V12Ha-Ras mice were of a mixed
CD1;FVB/N;C57BL/6 background. Doxycycline was dissolved in drinking water
(2mgml 1 with 5% sucrose) and administered to the animals. Control animals
received 5% sucrose.
Tissue preparation and histology. Mouse brains were removed and either frozen
in OCT or ﬁxed overnight in Zinc-buffered formalin and processed for parafﬁn
embedding. For histological analysis, tissue sections (5 mm) were stained with
haematoxylin and eosin.
Immunohistochemistry. For immunohistochemical analysis, tissue sections were
de-parafﬁnized, rehydrated and subjected to high temperature antigen retrieval in
10mM citrate buffer (pH 6.0). The following primary antibodies were used: rabbit
monoclonal anti-Ki67 (clone SP6, Lab Vision, 1:100) rabbit polyclonal anti-GFAP
(Novus Biologicals, 1:100), anti-nestin (Millipore, 1:100). These primary antibodies
were applied for 2 h in blocking buffer (2.5% BSA, 5% goat serum, 0.3% Triton
X-100 in PBS), followed by species-appropriate secondary Alexa Fluor 488 dye
conjugated antibodies (Amersham) or Vectastain ABC kit and DAB reagents
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(a) Patient-derived neurosphere cultures derived from a resected human glioblastoma were infected with a lentiviral vector harbouring a doxycycline-
regulatable Omomyc expression cassette. Myc inhibition by Omomyc decreases the number of spheres after 2 weeks of doxycycline treatment in culture.
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self-renewal ability. Neurospheres were dissociated into a single-cell suspension and 500 cells per well were added to a 96-well plate. The number of
spheres was counted after 2–4 weeks in the presence or absence of doxycycline. The meanþ s.e.m. is shown (n¼ 5). P-values were calculated by a
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expression (n¼ 6), or with sucrose as the control (n¼6). P¼0.04 by log-rank test. (d) Omomyc expression increases the number of aberrant nuclei in
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(Vector Laboratories). Fluorescence antibody-labeled slides were mounted in
DAKO ﬂuorescent mounting medium containing 1 mgml 1 Hoechst counterstain.
HRP-conjugated secondary antibodies were visualized by DAB staining (Vector
Laboratories). Apoptotic cells were detected with ApopTag Detection kit
(Chemicon International). Images were obtained with an Axiovert S100 TV
inverted ﬂuorescence microscope (Zeiss) and Open Lab 3.5.1 software, or with
an Axiovert 100 inverted microscope (Zeiss) equipped with a Hamamatsu Orca
digital camera.
NPG isolation and culture. NPGs were isolated from the SVZ of adult mice.
Brains were dissected and washed in Hank’s buffer (Gibco). Tissue samples were
minced, digested for 40min with 0.05% trypsin, triturated and passed through a
45mm cell strainer (BD Biosciences) to obtain a single-cell suspension. Cells were
seeded in serum-free neurobasal medium (Gibco) supplemented with 20 ngml 1
of Human bFGF (Gibco), 20 ngml 1 EGF (Sigma), Heparin (Sigma), B27 (Gibco),
pen/strep and glutamine. Cells were grown at 37 C in 5% CO2.
NPG cell growth, Trypan blue exclusion assay and BrdU staining. A total of 105
cells were seeded in triplicate in 12-well plates. They were then counted daily using
a Neubauer hemocytometer for 3 days, and cell death was estimated by Trypan
blue dye exclusion assay. On the third day, cells were incubated for 5 h with
the BrdU substrate (Roche), collected and ﬁxed overnight in 70% ethanol.
Staining with the BrdU antibody (BD Biosciences) was performed following the
manufacturer’s instructions. Cells were then counterstained with propidium iodide
and analysed with a FacsCanto ﬂow cytometer (BD Biosciences). Analysis was
performed using FlowJo software.
NPG immunoﬂuorescence. NPGs were centrifuged with CytoSpin (Eppendorf) to
cause them to adhere onto slides and ﬁxed in 4% paraformaldehyde. Fixed cells
were blocked with 5% BSA–0.1% Triton and then incubated with rabbit mono-
clonal anti-Ki67 (clone SP6, Lab Vision, 1:100) and rabbit polyclonal anti-GFAP
(Novus Biologicals, 1:500) overnight and counterstained with Hoechst. Images
were collected with an Axiovert S100 TV inverted ﬂuorescence microscope (Zeiss)
and Open Lab 3.5.1 software.
NPG self-renewal assay. To evaluate the self-renewal capacity of NPGs, a clonal
colony-forming assay was used to measure the proportion of cells that were able to
make new neurospheres. Single-cell dissociated NPGs were seeded in triplicate into
24- or 96-well plates with 500 cells per well, and the number of newly formed
neurospheres was counted after 3–4 weeks.
b-galactosidase staining. b-galactosidase staining was performed as described in
the protocol (Cell Signaling). GBM cells were incubated for 2 days in the presence
of X-gal to visualize the positive blue cells.
RNA and protein analysis. Cells grown and treated or not with doxycycline for 3
days were either used for RNA extraction with a RNAeasy kit (Qiagen) according
to manufacturer’s instructions, or lysed in RIPA buffer with proteases and
phosphatases inhibitors (Roche). RNA was retro-transcribed with the iScript cDNA
Synthesis Kit (Bio-Rad) and quantitative PCR with reverse transcription was
performed using the following Taqman probe for Omomyc: 50-/56-FAM/ATTTC
AGAAATGAGCTTTTGCGTCTC/36-TAMSp/-30 . Protein extracts were run on
10% or 12% precast gels (Life Technologies), transferred to PVDF membranes
(Millipore) and incubated with antibodies against SAE1 (Novus Biologicals,
1:1,000), PTP1B (BD Biosciences, 1:2,000), FLAG (Sigma, 1:4,000) or actin
(Sigma, 1:200,000). Complete western blot images are included as Supplementary
Fig. 5.
U87MG and U373MG culture. Human GBM U87MG and U373MG cell lines
were maintained in Dulbecco’s Modiﬁed Eagle’s medium supplemented with 10%
fetal bovine serum, glutamine (2mM), penicillin (50 units ml 1), and streptomy-
cin (50 gml 1) at 37 C in 5% CO2. For growth curves and cell viability assays, 104
cells were seeded in triplicate in 24-well plates. Cells were counted daily using a
Neubauer hemocytometer for 5 days, while cell death was quantiﬁed by Trypan
blue dye exclusion assay.
For the quantiﬁcation of multinucleated cells, cells were seeded and ﬁxed with
4% paraformaldehyde on coverslips 48, 72 and 120 h after the infection with
retroviruses producing either GFP or the fusion protein GFP-Omomyc. Cells were
then mounted on microscope slides with 40 ,6-diamidino-2-phenylindole (DAPI)-
containing Vectashield mounting solution. Images of around 2,000 cells were
acquired using a ﬂuorescence microscope (Zeiss) with a  20 objective. The
number of total and GFPþ cells with a number of nuclei 43 were counted.
For mitosis analysis, cells were seeded on coverslips in a six-well plate and ﬁxed
72 h after the infection with retroviruses producing either GFP or the fusion
protein GFP-Omomyc. Cells were then permeabilized in PBS containing 0.2%
Triton X-100 and blocked in 5% BSA. a-Tubulin was detected using a mouse
monoclonal primary antibody (Sigma, T9026, 1:100) and a Cy3 secondary antibody
(Jackson ImmunoResearch, 1:10). After immunostaining, cells were mounted on
microscope slides with DAPI-containing Vectashield mounting solution (Vector
Laboratories). For both Omomyc-expressing and control cells, images of 48
different mitoses were acquired using a ﬂuorescence microscope (Zeiss) with a
 63 objective.
Viral vectors and infections. Omomyc DNA was cloned into the pEGFP retro-
viral vector (Clontech). A total of 2.5 106 293T cells were seeded on 60-mm
plates and co-transfected with packaging plasmids Plp1, Plp2, PlpV/SVG
(Invitrogen) and pEGFP or pEGFP-Omomyc retroviral constructs using CaPO4
method. Supernatant was collected twice during the 2 days following transfection.
The day before transfection, 1.5 106 U87MG cells were seeded on 35-mm
plates. Cells were then infected with 293T cells-derived supernatant containing
retroviruses and polybrene (4 mgml 1).
Omomyc was cloned into the pTRIPZ lentiviral vector (Open Biosystems,
Thermo Scientiﬁc) and the shRNA sequences removed. For infections, 293T cells
were seeded at 70% conﬂuence and the following morning 25 mM chloroquinone
added. Two hours later, 293 cells were transfected with pTRIPZ-Omomyc plus the
lentiviral vectors pMD2G and psPAX2 by the CaPO4 method. The medium was
changed the following day and sodium butyrate added at 5mM. Viral supernatants
were harvested on the subsequent 2 days, ﬁltered and added to target cells with
polybrene (0.8 mgml 1).
Patient-derived neurosphere culture and orthotopic inoculation. Neurospheres
were isolated, cultured and inoculated as described previously35. Brieﬂy, tumour
cells from disaggregated patient-derived neurospheres were stereotactically
inoculated into the corpus striatum of the right brain hemisphere (1mm anterior
and 1.8mm lateral to the bregma; 2.5mm intraparenchymal) of 9-week-old
NOD-SCID mice (Charles River Laboratories). Three weeks after transplantation,
the animals received doxycycline dissolved in drinking water (2mgml 1 with 5%
sucrose). Control animals received only sucrose. Mice were euthanized when they
presented with neurological symptoms or a signiﬁcant loss of weight.
Statistical analysis. Data are shown in bar graphs as meansþ standard deviation
(s.d.), or as standard error (s.e.) if indicated. P-values were calculated using Stu-
dent’s t-test to compare groups, or log-rank test for Kaplan–Meier curves.
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